In nonsecretory, oligo-secretory, and light chain multiple myeloma patients, serial sFLC evaluation could precede biochemical and clinical disease progression, even in extramedullary relapse, thus initiating early treatment with novel anti-MM agents.
Serum free light chains and multiple myeloma: Is it time to extend their application?
Markovic U.;Tibullo D.;Giubbolini R.;Romano A.;Parrinello N. L.;Cannizzaro M. T.;Di Raimondo F.;
2020-01-01
Abstract
In nonsecretory, oligo-secretory, and light chain multiple myeloma patients, serial sFLC evaluation could precede biochemical and clinical disease progression, even in extramedullary relapse, thus initiating early treatment with novel anti-MM agents.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Serum free light chains and multiple myeloma.pdf
accesso aperto
Tipologia:
Versione Editoriale (PDF)
Dimensione
596.14 kB
Formato
Adobe PDF
|
596.14 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
